Mark Cobbold

VP Discovery, Oncology R&D at AstraZeneca
Summary
Dr. Mark Cobbold is a prominent figure in the fields of Immunology and Immunotherapy, having completed his PhD in this area at the University of Birmingham.
He has held various key positions in prestigious organizations, showcasing a rich and varied professional background. Currently, he serves as the VP of Oncology Early Discovery at AstraZeneca, a leading global biopharmaceutical company.
Prior to his role at AstraZeneca, Dr. Cobbold was the Scientific Co-Founder at GigaMune, Gritstone Oncology, Revitope, PhosImmune, Inc., and Serascience, underlining his entrepreneurial spirit and involvement in cutting-edge ventures.
His academic contributions are equally impressive, having held positions at esteemed institutions such as the Broad Institute, Massachusetts General Hospital, Harvard University, and the University of Birmingham. These positions include roles as an Associate Professor of Medicine, Reader in Translational Immunology, and Senior Clinical Research Fellow.
Dr. Cobbold's expertise spans across different facets of the scientific and medical domains, making him a well-rounded professional with a wealth of experience in both research and industry settings.